Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q1 FY26 results · Apr–Jun 2025
Astec LifeSciences reported revenue from operations of ₹91.08 crore (up 31.3% from Q1 FY25) and net loss of ₹33.03 crore for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 91.08 | 69.37 | +31.3% | 119.53 | −23.8% |
| Other income | 0.51 | 0.92 | −45.2% | 0.79 | −36.0% |
| Total income | 91.59 | 70.30 | +30.3% | 120.32 | −23.9% |
| Profit before tax | (33.02) | (61.64) | Loss narrowed | (15.66) | Loss widened |
| Net profit for the period | (33.03) | (39.72) | Loss narrowed | (16.08) | Loss widened |
| Attributable to shareholders of the company | (33.04) | (39.72) | Loss narrowed | (16.09) | Loss widened |
| EPS, basic (₹) | (16.85) | (20.26) | Loss narrowed | (8.20) | Loss widened |
| Net margin (%) | -36.3 | -57.2 | -13.5 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 91.08 | 69.37 | +31.3% | 119.53 | −23.8% |
| Other income | 0.49 | 0.91 | −46.4% | 0.78 | −37.4% |
| Total income | 91.57 | 70.28 | +30.3% | 120.30 | −23.9% |
| Profit before tax | (33.06) | (61.67) | Loss narrowed | (15.69) | Loss widened |
| Net profit for the period | (33.06) | (39.74) | Loss narrowed | (16.10) | Loss widened |
| EPS, basic (₹) | (16.86) | (20.26) | Loss narrowed | (8.21) | Loss widened |
| Net margin (%) | -36.3 | -57.3 | -13.5 |
Consolidated
- Filed with BSE
- 28 Jul 2025, 19:18 IST
- Board meeting
- 28 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Jul 2025, 19:18 IST
- Board meeting
- 28 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE